Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon in chronic hepatitis B

G Saracco1, M Rizzetto, G Verme

  • 1Department of Gastroenterology, Molinette Hospital, Torino, Italy.

Antiviral Research
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental electroactive consortia as reusable biosensing element for freshwater toxicity monitoring.

New biotechnology·2019
Same author

Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy?

Alimentary pharmacology & therapeutics·2017
Same author

Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy.

Irish journal of medical science·2017
Same author

Pathogenesis of chronic cluster headache and bouts: role of tryptamine, arginine metabolism and α<sub>1</sub>-agonists.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2017
Same author

Does Helicobacter pylori infection increase the risk of adult-onset asthma?

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Efficacy of amoxycillin and clarithromycin-based triple therapy for Helicobacter pylori eradication: a 10-year trend in Turin, Italy.

Panminerva medica·2015
Same journal

The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata.

Antiviral research·2026
Same journal

Ginsenoside Rb2-based inactivation enables a Zika vaccine that maintains pregnancy and protects offspring against virus.

Antiviral research·2026
Same journal

ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection.

Antiviral research·2026
Same journal

Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].

Antiviral research·2026
Same journal

Effects of RNA polymerase inhibitors on nucleotidylylation of human norovirus VPg.

Antiviral research·2026
Same journal

Human monoclonal antibodies from donors vaccinated with recombinant vaccinia vaccine targeting A35 and B6 effectively inhibit orthopoxvirus spread and infection.

Antiviral research·2026
See all related articles

Interferon-alpha therapy for chronic hepatitis B (HBV) shows a 40% response rate, with sustained benefits in most responders. However, certain patient groups respond less effectively, and combination therapies offer no added advantage over interferon alone.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (HBV) is a significant global health concern.
  • Interferon-alpha (IFN-α) is a standard treatment for HBV infection.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of interferon-alpha treatment in chronic hepatitis B patients.
  • To identify factors influencing treatment response and assess combination therapy benefits.

Main Methods:

  • Treatment involved 4-6 months of alternate-day interferon-alpha at a minimum dosage of 5 million units/m².
  • Patient response was assessed by clearance of replicative markers, normalization of transaminases, and histologic improvement.
  • Subgroup analyses considered patient demographics and viral load.

Related Experiment Videos

Main Results:

  • A 40% therapeutic response rate was observed, with long-term benefits maintained in approximately 90% of responders.
  • Lower response rates were noted in Oriental HBV carriers, children, immunodeficient, and highly viraemic patients.
  • Combination therapies did not demonstrate superior efficacy compared to interferon-alpha monotherapy.

Conclusions:

  • Interferon-alpha effectively inhibits HBV replication but requires improved patient selection for sustained remission.
  • Further research into novel therapeutic regimens and cost-benefit optimization is warranted.